Executive Management Team
Our leadership team creates, hones and maintains our company’s focus and commitment to excellence in everything we do. The tireless work of these individuals continues to drive our growth, success and shareholder value.
Learn more about the dynamic people leading the way for Anika Therapeutics.
Cheryl Blanchard, Ph.D.
President and Chief Executive Officer
On April 26, 2020, Cheryl Blanchard, Ph.D. was appointed President and Chief Executive Officer, after serving as interim Chief Executive Officer since February 2020. Dr. Blanchard joined the Board of Directors of Anika Therapeutics, Inc. in August 2018. Prior to her work as an executive officer with Anika, she served as the President and Chief Executive Officer of Microchips Biotech, Inc., a venture-backed biotechnology company developing regenerative medicine and drug delivery products, from 2014 until its sale to Daré Bioscience, Inc. in November 2019. Since 2012, Dr. Blanchard has also been a Principal at Blanchard Consulting, LLC which provides scientific, regulatory, and business strategy consulting services to medical device companies and private equity clients. From 2000 to 2012, she served in various officer positions of Zimmer, Inc. (now Zimmer Biomet), a medical device company focused on musculoskeletal products, including as the Senior Vice President, Chief Scientific Officer, and general manager of Zimmer Biologics. She was also a member of Zimmer’s executive committee and founded, built and led Zimmer’s Joint Preservation/Regenerative Medicine business. Prior to joining Zimmer, Dr. Blanchard built and led the medical device practice at Southwest Research Institute. Dr. Blanchard received her M.S. and Ph.D. in Materials Science and Engineering at the University of Texas at Austin and received her B.S. in Ceramic Engineering at Alfred University. Until her appointment as interim Chief Executive Officer, Dr. Blanchard served as a member of Anika’s Compensation Committee and Governance and Nominating Committee. She has served as a director of Neuronetics (NASDAQ: STIM) since February 2019 and as a director of Daré Bioscience, Inc. (NASDAQ: DARE) since November 2019.
Chief Financial Officer
On April 1, 2013, Sylvia Cheung was appointed as Chief Financial Officer. Ms. Cheung brings to Anika a substantial number of years of financial and general management experience. Prior to her current position, Sylvia was the Vice President of Strategic Processes; and previously, she served as the General Manager for the company’s Italian-based subsidiary, Anika S.r.l. She joined Anika as Controller in 2005. In addition to fulfilling wide-ranging financial responsibilities as Controller, Sylvia led the company’s integration of Anika S.r.l. subsequent to its acquisition in 2009.
Prior to Anika, she held a series of progressively responsible financial management positions at Transkaryotic Therapies, Inc. From 1995 to 2000, Sylvia worked for PricewaterhouseCoopers, LLP as an Audit Senior Associate.
Sylvia holds a bachelor of business administration degree in accounting from the University of Massachusetts in Amherst, a master’s degree in business administration from Boston University, and is a Certified Public Accountant (inactive).
Executive Vice President of Business Development and Strategic Planning
Jim Loerop joined Anika Therapeutics on July 8th, 2019 as the Company’s Executive Vice President of Business Development and Strategic Planning. Most recently, Mr. Loerop served as Chief Corporate Development Officer for Lupin Pharmaceuticals where he was a member of the company’s Executive Leadership Team and was responsible for global business development and corporate development activities. Prior to his work with Lupin, Jim held senior leadership roles at various companies in the pharmaceutical and life sciences industry, including at Alexion Pharmaceuticals as Senior Vice President of Global Business Development, GlaxoSmithKline as Vice President of North America Business Development, and Steifel Laboratories as Senior Vice President of Global Corporate Development prior to GSK’s acquisition of Stiefel.
Mr. Loerop holds a B.S. in Marketing from Western Michigan University.
Executive Vice President, General Counsel and Corporate Secretary
David Colleran joined Anika Therapeutics, Inc. on March 4, 2020 as the Company’s Executive Vice President, General Counsel and Corporate Secretary. Mr. Colleran leads Anika’s global legal organization, including corporate governance and compliance. Most recently, David served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Insulet Corporation, a publicly traded, global medical device and drug delivery company. Prior to Insulet, he held the role of Vice President and General Counsel at Covidien, a global manufacturer of medical devices and supplies acquired by Medtronic, and Corporate Counsel at Ocean Spray Cranberries. Mr. Colleran began his career as a corporate attorney at Choate, Hall & Stewart.
David holds a B.A. in Political Science from Boston College and a J.D. from Boston College Law School, and he is admitted to the Massachusetts Bar.
Executive Vice President of Human Resources
Tom Finnerty joined Anika Therapeutics, Inc. as the Company’s Chief Human Resources Officer on October 30, 2017. Most recently, Tom was a strategic human capital consultant with Anika Therapeutics. Prior to his work at Anika, Tom was the Senior Vice President of Human Resources at Smith & Nephew where he was responsible for delivering value added programs, processes, and leadership in all areas of global human capital management to over 10,000 employees. Prior to his time at Smith & Nephew, Mr. Finnerty served as Executive Director of Human Resources at Novartis/Chiron Diagnostics. Tom launched his career in human resources at The Foxboro Company, a global enterprise focused on designing and manufacturing innovative process control products and systems.
Tom holds a Masters in Business Administration from Babson College, and a Bachelor of Science in Business from the University of Massachusetts.
President of Sports Medicine
On May 29, 2020, Mark Brunsvold was appointed as President of Sports Medicine. Mark joined Anika Therapeutics, Inc. in January of 2020 following the acquisition of Parcus Medical, LLC. Mark brings over 30 years of sports medicine manufacturing and operational leadership experience to Anika. Most recently, Mr. Brunsvold had served as President and Co-Founder of Parcus Medical, LLC. since 2007. Prior to this role, Mark was President and Founder of Machined Metals, Inc., serving as Vice President of Manufacturing following its acquisition by Arthrex, Inc. He has also served as President and Founder of Black Pearl Marine and Future Machine.
Senior Vice President of International Sales and Marketing
On May 29, 2020, James Chase was appointed as Senior Vice President of International Sales and Marketing. Mr. Chase first joined Anika Therapeutics, Inc. as Vice President of International Sales on August 6, 2018. Prior to Anika, James served as the Business Unit Director of the Sports Medicine Division of Smith & Nephew for the United Kingdom and Ireland. Prior to this role, Mr. Chase held several senior level leadership roles at Smith & Nephew, including General Manager UK/Ireland, Vice President Northern Europe, and Managing Director UK/Ireland. In these roles, he has successfully led large commercial teams generating revenue in excess of $300m.
James holds a B.E. in Electrical Engineering from Plymouth University (Honors), and an M.B.A. from The Open University.
Senior Vice President of Operations and Project Management
On May 29, 2020, Alexei Goraltchouk was appointed as Senior Vice President of Operations and Project Management. Mr. Goraltchouk first joined Anika Therapeutics, Inc. in June of 2018. Prior to Anika, Alex served as Vice President of Operations at Avedro, Inc. where he was responsible for managing all aspects of Clinical and Commercial Production, Technical Operations, Procurement, and Supply Chain Management for the organization. Prior to his work at Avedro, Mr. Goraltchouk held senior leadership roles in Operations, Supply Chain Management, and R&D for several firms including Allergan, Inc., Regeneron, Inc., and Biogen, Inc.
Alex holds a B.S. in Materials Engineering and an M.S. in Chemical Engineering from the University of Toronto, as well as an M.B.A. and M.S. in Finance from Indiana University. He is a Cornell Certified Six Sigma Black Belt and holds professional certifications from Stanford University (Genetics and Genomics), Massachusetts Institute of Technology (Supply Chain Management), and the Project Management Institute (Project Management Professional).
Vice President of Sales and Marketing, Americas
On May 29, 2020, Bart Bracy was appointed as Vice President of Sales and Marketing, Americas. Bart joined Anika Therapeutics, Inc. in January of 2020 following the acquisition of Parcus Medical, LLC. Bart brings over 30 years of sports medicine sales and marketing experience to Anika. Most recently, Bart had served as Senior Vice President of Parcus Medical, LLC., which he Co-Founded in 2007. Prior to this role, Bart held several sales and marketing leadership roles at Arthrex, Inc., Concept, Inc., now part of CONMED, Corp., Richards Medical, now part of Smith & Nephew, as well as several other sports medicine distribution companies.
Vice President of Research and Development
On May 29, 2020, Steven Ek was appointed as Vice President of Research and Development. Steve joined Anika Therapeutics, Inc. in February of 2020 following the acquisition of Arthrosurface, Inc. Steve brings over 30 years of product development experience to Anika. Most recently, Mr. Ek had served as President and CEO of Arthrosurface, Inc., which he Co-Founded in 2002. Prior to this role, Steve held several senior level research and development and engineering roles at Smith & Nephew, CONMED Corp., and Primo Medical Group.
Steve holds a B.E. in Materials Science and Engineering from the University of Florida.
Vice President of Regulatory Affairs, Quality, and Clinical Affairs
Mira Leiwant joined Anika Therapeutics, Inc. as the Company’s Vice President of Regulatory Affairs, Quality and Clinical Affairs on October 1, 2019. Most recently, Mira was Vice President of Regulatory Affairs at BTG International where she was responsible for the leadership of Interventional Oncology Regulatory functions and activities within the organization. Prior to her work at BTG International, Mira was the Senior Director of Regulatory and Quality Engineering at Lifecell Corporation where she oversaw the development of and led all Regulatory and Quality teams for the organization. Mira has also held senior leadership roles at a number of other Medical Device, Life Sciences, and Pharmaceutical organizations including Quality Assurance at Svelte Medical Systems, Inc., Vascular Therapies, and Micell Technologies. Mira began her career at Cordis Corporation.
Mira holds a M.E. in Mechanical Engineering, Bioengineering option and a B.S. in Mechanical Engineering, Bioengineering option, both from Cornell University, and is a Regulatory Affairs Certification (RAC) holder.